Table 2.

Treatment utilization and abstinence among intervention groups

	Control (n= 269)	Experimental (n= 267)	Unadjusted		Adjusteda
	%	%	ORb	P	ORb	P
Treatment utilization
Enrolled in provided phone counselingc
6 months	22.3	20.2	0.88	0.56	0.87	0.51
12 months	30.9	25.5	0.77	0.17	0.75	0.15
Used self-help materialsd
6 months	30.4	25.1	0.77	0.19	0.75	0.16
12 months	37.7	33.7	0.84	0.36	0.84	0.36
Used other counselingd
6 months	4.5	4.1	0.91	0.86	0.98	0.96
12 months	7.1	8.1	1.15	0.67	1.20	0.59
Used pharmacotherapyd
6 months	37.8	28.0	0.64	0.02	0.65	0.03
12 months	45.6	38.3	0.74	0.10	0.76	0.14
Abstinence
7 Day PPA – ITTe
6 months	14.1	12.0	0.83	0.46	0.77	0.33
12 months	14.9	13.1	0.86	0.56	0.80	0.38
7 Day PPA – Respondentsf
6 months	15.4	13.2	0.84	0.48	0.76	0.31
12 months	17.0	15.2	0.88	0.58	0.79	0.37
30 Day PPA - ITTe
6 months	10.8	6.4	0.56	0.07	0.51	0.04
12 months	13.0	10.9	0.82	0.44	0.77	0.34
30 Day PPA – Respondentsf
6 months	11.7	7.0	0.57	0.07	0.50	0.04
12 months	14.9	12.6	0.82	0.46	0.76	0.33

^aAnalyses adjusted for baseline FTND score, self-efficacy, number of quit attempts in prior year, likelihood of quitting in next month, and whether other smokers lived in the household.

^bOR = Odds Ratio

^cProportion who enrolled in the provided free phone-counseling program by each assessment, based on automated treatment records.

^dCumulative proportion who self-reported use of other smoking cessation treatments by each follow-up. Counseling included programs other than the provided phone-counseling program. Pharmacotherapy included use of any medications to quit smoking, including: nicotine replacement products, bupropion, and varenicline.

^eITT PPA = intent to treat point prevalent abstinence.

^fPPA for only those participants who provided smoking status data at follow-up.